keyword
MENU ▼
Read by QxMD icon Read
search

radionuclide therapy

keyword
https://www.readbyqxmd.com/read/28347131/preclinical-in-vivo-cancer-straightway-to-patients
#1
Marion de Jong, Stephen Mather, Theodosia Maina
Detection of useful cellular targets has strongly stimulated personalized tumor-targeted imaging and therapy approaches, also involving synthesis and evaluation of nuclear imaging probes with potential for clinical applications. Reviews of preclinical and translational studies concerning such probes, including radiolabeled antibodies, nanobodies, affibodies, peptides, small molecule inhibitors, and nanoparticles, are presented in this issue. As most tracers described in these articles have been developed for the field of cancer imaging and radionuclide therapy, the current article on preclinical studies will focus on cancer research as well...
June 2017: Quarterly Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28338640/metal-based-psma-radioligands
#2
REVIEW
Eleni Gourni, Gjermund Henriksen
Prostate cancer is one of the most common malignancies for which great progress has been made in identifying appropriate molecular targets that would enable efficient in vivo targeting for imaging and therapy. The type II integral membrane protein, prostate specific membrane antigen (PSMA) is overexpressed on prostate cancer cells in proportion to the stage and grade of the tumor progression, especially in androgen-independent, advanced and metastatic disease, rendering it a promising diagnostic and/or therapeutic target...
March 24, 2017: Molecules: a Journal of Synthetic Chemistry and Natural Product Chemistry
https://www.readbyqxmd.com/read/28320783/pitfalls-in-the-response-evaluation-after-prrt-with-177-lu-dota-0-tyr-3-octreotate
#3
Tessa Brabander, Wouter Van der Zwan, Jaap J M Teunissen, Boen L R Kam, Wouter W de Herder, R A Feelders, Eric P Krenning, Dik Kwekkeboom
Peptide receptor radionuclide therapy (PRRT) with [177Lu-DOTA0,Tyr3]octreotate (177Lu-DOTATATE) is a treatment with good results in patients with metastatic gastroenteropancreatic neuroendocrine tumour (GEPNETs). However, there are some pitfalls that should be taken into consideration when evaluating the treatment response after PRRT. 354 Dutch patients with GEPNETs who were treated with 177Lu-DOTATATE between March 2000 and December 2011 were retrospectively selected. Liver function parameters and chromogranin A were measured before each therapy and in follow-up...
March 20, 2017: Endocrine-related Cancer
https://www.readbyqxmd.com/read/28319500/clinical-response-profile-of-metastatic-advanced-pulmonary-neuroendocrine-tumors-to-peptide-receptor-radionuclide-therapy-with-177lu-dotatate
#4
Rahul V Parghane, Sanjay Talole, Kumar Prabhash, Sandip Basu
OBJECTIVES: The aims of this study were to perform multiparametric response assessment of metastatic/advanced pulmonary neuroendocrine tumors (NETs) to Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) (clinical, biochemical, molecular/structural imaging, and survival assessment) and to study the relationship between response, mortality, and overall survival with dual-tracer molecular imaging parameters. METHODS: Twenty-two patients (6 women, 16 men; median age, 44 years; range, 16-72 years) of histopathologically proven pulmonary NETs with metastatic/advanced disease were included and analyzed retrospectively...
March 17, 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/28316066/long-term-results-and-tolerability-of-tandem-peptide-receptor-radionuclide-therapy-with-90-y-177-lu-dotatate-in-neuroendocrine-tumors-with-respect-to-the-primary-location-a-10-year-study
#5
Jolanta Kunikowska, Dariusz Pawlak, Marianna I Bąk, Beata Kos-Kudła, Renata Mikołajczak, Leszek Królicki
INTRODUCTION: The peptide receptor radionuclide therapy (PRRT) with (90)Y and (177)Lu is a form of molecular targeted therapy for inoperable or disseminated neuroendocrine tumors (NET). AIM: The aim of the study was to evaluate clinical results and long-term side effects of tandem (90)Y /(177)Lu-DOTATATE therapy in patients with NET. Additionally, we evaluated clinical results with reference to the primary site. MATERIALS AND METHODS: 59 patients with disseminated NET were included in the study prospectively...
March 18, 2017: Annals of Nuclear Medicine
https://www.readbyqxmd.com/read/28303694/lutetium-177-psma-radionuclide-therapy-for-men-with-prostate-cancer-a-review-of-the-current-literature-and-discussion-of-practical-aspects-of-therapy
#6
REVIEW
Louise Emmett, Kathy Willowson, John Violet, Jane Shin, Ashley Blanksby, Jonathan Lee
Prostate-specific membrane antigen (PSMA) is a receptor on the surface of prostate cancer cells that is revolutionising the way we image and treat men with prostate cancer. New small molecule peptides with high-binding affinity for the PSMA receptor have allowed high quality, highly specific PET imaging, in addition to the development of targeted radionuclide therapy for men with prostate cancer. This targeted therapy for prostate cancer has, to date, predominately used Lutetium 177 (Lu) labelled PSMA peptides...
March 2017: Journal of Medical Radiation Sciences
https://www.readbyqxmd.com/read/28302234/tuberculous-dactylitis-with-concomitant-thyroid-involvement-a-rare-presentation-of-childhood-tuberculosis
#7
Sobia Qamar, Farrah Naz, Samia Naz, Iftikhar Ejaz
Extrapulmonary tuberculosis rarely presents as thyroid involvement along with other manifestations, and poses a diagnostic challenge on account of paucibacillary nature of disease. In general, the diagnosis of tuberculosis is based on epidemiological risk factors, clinical features, imaging studies, in addition to a positive skin testing or Interferon Gamma Release Assay (IGRA). A 14-year boy presented with history of fever and weight loss for one year. On examination, he had painful swelling of fingers and toes along with a painless thyroid nodule and squint...
March 2017: Journal of the College of Physicians and Surgeons—Pakistan: JCPSP
https://www.readbyqxmd.com/read/28302144/a-dosimetric-model-for-the-heterogeneous-delivery-of-radioactive-nanoparticles-in-vivo-a-feasibility-study
#8
Andrew B Satterlee, Peter Attayek, Bentley Midkiff, Leaf Huang
ᅟ: Accurate and quantitative dosimetry for internal radiation therapy can be especially challenging, given the heterogeneity of patient anatomy, tumor anatomy, and source deposition. Internal radiotherapy sources such as nanoparticles and monoclonal antibodies require high resolution imaging to accurately model the heterogeneous distribution of these sources in the tumor. The resolution of nuclear imaging modalities is not high enough to measure the heterogeneity of intratumoral nanoparticle deposition or intratumoral regions, and mathematical models do not represent the actual heterogeneous dose or dose response...
March 17, 2017: Radiation Oncology
https://www.readbyqxmd.com/read/28301262/-213-bi-labeled-prostate-specific-membrane-antigen-targeting-agents-induce-dna-double-strand-breaks-in-prostate-cancer-xenografts
#9
Julie Nonnekens, Kristell L S Chatalic, Janneke D M Molkenboer-Kuenen, Cecile E M T Beerens, Frank Bruchertseifer, Alfred Morgenstern, Joke Veldhoven-Zweistra, Margret Schottelius, Hans-Jürgen Wester, Dik C van Gent, Wytske M van Weerden, Otto C Boerman, Marion de Jong, Sandra Heskamp
BACKGROUND: Up to now, prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy mainly focused on β-emitting radionuclides. Herein, two new (213)Bi-labeled agents for PSMA-targeted α therapy of prostate cancer (PCa) are reported. METHODS: The biodistribution of (213)Bi-labeled small-molecule inhibitor PSMA I&T and nanobody JVZ-008 was evaluated in mice bearing PSMA-positive LNCaP xenografts. DNA damage response was followed using LNCaP cells and LNCaP xenografts...
March 2017: Cancer Biotherapy & Radiopharmaceuticals
https://www.readbyqxmd.com/read/28291159/67cu-radiolabeling-of-a-multimeric-rgd-peptide-for-%C3%AE-v%C3%AE-3-integrin-targeted-radionuclide-therapy-stability-therapeutic-efficacy-and-safety-studies-in-mice
#10
Zhao-Hui Jin, Takako Furukawa, Tomoyuki Ohya, Mélissa Degardin, Aya Sugyo, Atsushi B Tsuji, Yasuhisa Fujibayashi, Ming-Rong Zhang, Tatsuya Higashi, Didier Boturyn, Pascal Dumy, Tsuneo Saga
OBJECTIVE: Copper-67 (Cu) is one of the most promising radionuclides for internal radiation therapy. Globally, several projects have recently been initiated for developing innovative approaches for the large-scale production of Cu. Encouraged by these, we performed Cu-radiolabeling of a tetrameric cyclic Arg-Gly-Asp (cRGD) peptide conjugate, cyclam-RAFT-c(-RGDfK-)4, which selectively targets αVβ3 integrin (αVβ3), the transmembrane receptor involved in tumor invasion, angiogenesis, and metastasis...
April 2017: Nuclear Medicine Communications
https://www.readbyqxmd.com/read/28287131/separation-of-nuclear-isomers-for-cancer-therapeutic-radionuclides-based-on-nuclear-decay-after-effects
#11
R Bhardwaj, A van der Meer, S K Das, M de Bruin, J Gascon, H T Wolterbeek, A G Denkova, P Serra-Crespo
(177)Lu has sprung as a promising radionuclide for targeted therapy. The low soft tissue penetration of its β(-) emission results in very efficient energy deposition in small-size tumours. Because of this, (177)Lu is used in the treatment of neuroendocrine tumours and is also clinically approved for prostate cancer therapy. In this work, we report a separation method that achieves the challenging separation of the physically and chemically identical nuclear isomers, (177m)Lu and (177)Lu. The separation method combines the nuclear after-effects of the nuclear decay, the use of a very stable chemical complex and a chromatographic separation...
March 13, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28284506/sudden-cardiac-death-the-role-of-imaging
#12
Pieter van der Bijl, Victoria Delgado, Jeroen J Bax
Sudden cardiac death (SCD) is defined as "a non-traumatic, unexpected, fatal event occurring within one hour of the onset of symptoms in an apparently healthy subject", and it causes a fifth of all deaths worldwide. It often occurs in individuals not previously known with cardiac disease, which makes prevention challenging. The mechanism underlying SCD is thought to be a trigger (e.g. ischemia) acting upon a substrate (e.g. scar), causing a lethal arrhythmia. Primary prevention refers to patients at high risk of SCD and secondary prevention to those who have had an aborted episode of SCD...
March 6, 2017: International Journal of Cardiology
https://www.readbyqxmd.com/read/28284122/the-importance-of-bmi-in-dosimetry-of-153-sm-edtmp-bone-pain-palliation-therapy-a-monte-carlo-study
#13
Maryam Fallahpoor, Mehrshad Abbasi, Ali Asghar Parach, Faraz Kalantari
Using digital phantoms as an atlas compared to acquiring CT data for internal radionuclide dosimetry decreases patient overall radiation dose and reduces the required analysis effort and time for organ segmentation. The drawback is that the phantom may not match exactly with the patient. We assessed the effect of varying BMIs on dosimetry results for a bone pain palliation agent, (153)Sm-EDTMP. The simulation was done using the GATE Monte Carlo code. Female XCAT phantoms with the following different BMIs were employed: 18...
February 28, 2017: Applied Radiation and Isotopes
https://www.readbyqxmd.com/read/28275848/-reliability-of-venous-blood-gas-analysis-and-radionuclide-angiography-in-post-traumatic-dystrophy
#14
A Scola, E Scola
BACKGROUND: The diagnosis "post-traumatic dystrophy" (PTD) was first defined with clinical and paraclinical criteria by Scola et al. in 2013. OBJECTIVES: The objectivity and reliability of the paraclinical criteria (venous blood gas analysis [vBGA], radionuclide angiography [RNA]), and recommendations for therapy should be assessed in a prospective study. MATERIALS AND METHODS: In five patients with clinical signs of post-traumatic nonbacterial inflammation of the hand, both diagnosis and a 3‑week hospital treatment were carried out in accordance with the publication mentioned above...
March 8, 2017: Der Unfallchirurg
https://www.readbyqxmd.com/read/28267454/from-bench-to-bed-new-gastrin-releasing-peptide-receptor-directed-radioligands-and-their-use-in-prostate-cancer
#15
REVIEW
Theodosia Maina, Berthold A Nock
Gastrin-releasing peptide receptors (GRPRs) are overexpressed in prostate and breast cancer, and are therefore attractive molecular targets for diagnosis and therapy with radiolabeled GRPR-directed peptide probes. The amphibian tetradecapeptide bombesin or the mammalian gastrin-releasing peptide and neuromedin C have been modified with a variety of chelators. As a result, labeling with radiometals attractive for SPECT or PET imaging and for radionuclide therapy has led to the development of peptide radioligands suitable for in vivo targeting of prostate cancer...
April 2017: PET Clinics
https://www.readbyqxmd.com/read/28265641/-nuclear-medicine-in-germany-updated-key-data-and-trends-from-official-statistics
#16
Dirk Hellwig, Jörg Marienhagen, Karin Menhart, Jirka Grosse
AIM: Updated presentation of the spectrum of nuclear medicine in-vivo examinations and therapies from officially available statistics on out-patient and in-patient care as well as trends of structural data on nuclear medicine in Germany. METHODS: Data from the German Federal Health Monitoring, from the frequency statistics of the statutory health insurance for out-patients and from the German Medical Association were used and supplemented by data from selective literature searches...
March 7, 2017: Nuklearmedizin. Nuclear Medicine
https://www.readbyqxmd.com/read/28263217/peptide-receptor-radionuclide-therapy-with-177-lu-octreotate-in-patients-with-somatostatin-receptor-expressing-neuroendocrine-tumors-six-years-assessment
#17
Mohammadali Hamiditabar, Muzammil Ali, Joseph Roys, Edward M Wolin, Thomas M OʼDorisio, David Ranganathan, Izabela Tworowska, Jonathan R Strosberg, Ebrahim S Delpassand
OBJECTIVES: Peptide receptor radionuclide therapy (PRRT) with radiolabeled somatostatin analogues is a promising treatment for patients with inoperable, well to moderately differentiated metastatic neuroendocrine tumors (NETs). In continuation of our novel study with the radionuclide lutetium Lu, we now present further results of Lu DOTATATE therapy in managing NETs and other somatostatin receptor-expressing tumors in a larger and more diverse patient group. PATIENTS AND METHODS: One hundred forty-four consecutive patients (85 men and 59 women; age range, 11-87 years; mean age, 58...
March 3, 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/28255795/-213-bi-psma-617-targeted-alpha-radionuclide-therapy-in-metastatic-castration-resistant-prostate-cancer
#18
Mike Sathekge, Otto Knoesen, Marian Meckel, Moshe Modiselle, Mariza Vorster, Sebastian Marx
No abstract text is available yet for this article.
March 2, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28255354/radionuclide-i-131-labeled-albumin-paclitaxel-nanoparticles-for-synergistic-combined-chemo-radioisotope-therapy-of-cancer
#19
Longlong Tian, Qian Chen, Xuan Yi, Guanglin Wang, Jie Chen, Ping Ning, Kai Yang, Zhuang Liu
Development of biocompatible/biodegradable materials with multiple functionalities via simple methods for cancer combination therapy has attracted great attention in recent years. Herein, paclitaxel (PTX), a popular anti-tumor chemotherapeutic drug, is used to induce the self-assembly of human serum albumin (HSA) pre-labeled with radionuclide I-131, obtaining (131)I-HSA-PTX nanoparticles for combined chemotherapy and radioisotope therapy (RIT) of cancer. Such (131)I-HSA-PTX nanoparticles show prolonged blood circulation time, high tumor specific uptake and excellent intra-tumor penetration ability...
2017: Theranostics
https://www.readbyqxmd.com/read/28254656/gefitinib-enhances-radiotherapeutic-effects-of-131-i-hegf-targeted-to-egfr-by-increasing-tumor-uptake-of-hegf-in-tumor-xenografts
#20
Lu Xia, He Peng, Luo Zhiqiang, Zhang Xiaoli
Gefitinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor which has been proven effective for cancer treatment. In this study, we sought to determine whether gefitinib could increase the in vivo tumor uptake of human (131)I-EGF ((131)I-hEGF), thereby enhancing the potential of hEGF as a vehicle for EGFR-targeted radionuclide therapy. Western blot analysis was conducted to detect the effects of gefitinib on EGFR expression in human head and neck squamous carcinoma cell line UM-SCC-22B...
February 4, 2017: Nuclear Medicine and Biology
keyword
keyword
100899
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"